Screener
Bicara Therapeutics BCAX EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Bicara Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Bicara Therapeutics’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:03 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-033429
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Net loss before income taxes | (56,159) | (36,774) |
| Income tax expense | (52) | (72) |
| Net loss | $(56,211) | $(36,846) |
| Net Loss per share, basic and diluted | $(0.93) | $(0.68) |
| Weighted-average number common shares outstanding, basic and diluted | 60,717,041 | 54,456,515 |
| Other comprehensive loss: | ||
| Unrealized loss on marketable securities, net of tax | (486) | — |
| Total other comprehensive loss | (486) | — |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Bicara Therapeutics's EPS (diluted)?
- Bicara Therapeutics (BCAX) reported EPS (diluted) of -$0.93 in Q1 2026.
- How has Bicara Therapeutics's EPS (diluted) changed year-over-year?
- Bicara Therapeutics's EPS (diluted) decreased by 36.8% year-over-year, from -$0.68 to -$0.93.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Bicara Therapeutics's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude